Pancreaticoduodenectomy versus limited resection for duodenal gastrointestinal stromal tumors: a systematic review and meta-analysis
Tóm tắt
By comparing the long-term prognostic outcomes after pancreaticoduodenectomy (PD) and limited resection (LR), this study aimed to investigate the optimal surgical modality for duodenal gastrointestinal stromal tumors (GISTs). Two authors independently searched PubMed, Web of Science, Embase, and the Cochrane Library for published articles comparing the long-term prognostic and clinicopathological factors of duodenal GIST patients undergoing PD versus LR. Relevant information was extracted and analyzed. After screening, 10 items comprising 623 cases were eventually included. This meta-analysis explicitly indicated that PD treatment was associated with worse long-term prognosis (hazard ratio = 1.93; 95% confidence interval [CI], 1.39–2.69; p < 0.001; I2 = 0) and more complications (odds ratio [OR] = 2.90; 95% CI, 1.90–4.42; p < 0.001; I2 = 10%) than LR treatment. Nevertheless, for duodenal GISTs, PD was related to the following clinicopathological features: invasion of the second part of the duodenum (OR = 3.39; 95% CI, 1.69–6.79; p < 0.001; I2 = 50%), high-degree tumor mitosis (> 5/50 high-power fields; OR = 2.24; 95% CI, 1.42–3.52; p < 0.001; I2 = 0), and high-risk classification (OR = 3.17; 95% CI; 2.13–4.71; p < 0.001; I2 = 0). Since PD is associated with worse long-term prognosis and more complications, its safety and efficacy should be ascertained. Our findings recommend the use of LR to obtain negative incision margins when conditions permit it.
Tài liệu tham khảo
Joensuu H, Fletcher C, Dimitrijevic S, Silbermand S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumors. Lancet Oncol. 2002;3(11):655–64.
Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:71.
Joensuu H, Vehtari A, Jaakko Riihimäki NT, Steigen SE, Brabec P, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13(3):265–74.
Coe TM, Fero KE, Fanta PT, Mallory RJ, Tang CM, Murphy JD, et al. Population-based epidemiology and mortality of small malignant gastrointestinal stromal tumors in the USA. J Gastrointest Surg. 2016;20(6):1132–40.
Kukar M, Kapil A, Papenfuss W, Groman A, Grobmyer SR, Hochwald SN. Gastrointestinal stromal tumors (GISTs) at uncommon locations: a large population based analysis. J Surg Oncol. 2015;111(6):696–701.
Crown A, Biehl TR, Rocha FG. Local resection for duodenal gastrointestinal stromal tumors. Am J Surg. 2016;211(5):867–70.
Shen C, Chen H, Yin Y, Chen J, Han L, Zhang B, et al. Duodenal gastrointestinal stromal tumors: clinicopathological characteristics, surgery, and long- term outcome. BMC Surg. 2015;15:98.
Beham A, Schaefer IM, Cameron S, von Hammerstein K, Füzesi L, Ramadori G, et al. Duodenal GIST: a single center experience. Int J Color Dis. 2013;28(4):581–90.
Chung JC, Kim HC, Hur SM. Limited resections for duodenal gastrointestinal stromal tumors and their oncologic outcomes. Surg Today. 2016;46(1):110–6.
Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer. 2016;19:3–14.
Gervaz P, Huber O, Morel P. Surgical management of gastrointestinal stromal tumours. Br J Surg. 2009;96(6):567–78.
Johnston FM, Kneuertz PJ, Cameron JL, Sanford D, Fisher S, Turley R, et al. Presentation and Management of Gastrointestinal Stromal Tumors of the duodenum: a multi-institutional analysis. Ann Surg Oncol. 2012;19(11):3351–60.
Frankel TL, Chang AE, Wong SL. Surgical options for localized and advanced gastrointestinal stromal tumors. J Surg Oncol. 2011;104(8):882–7.
Goh BKP, Chow PKH, Kesavan S, Yap WM, Wong WK. Outcome after surgical treatment of suspected gastrointestinal stromal tumors involving the duodenum: is limited resection appropriate? J Surg Oncol. 2008;97(5):388–91.
Colombo C, Ronellenfitsch U, MD ZY, Rutkowski P, Miceli R, Bylina E, et al. Clinical, pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival: a multi-center study. Ann Surg Oncol. 2012;19(11):3361–7.
Bourgouin S, Hornez E, Guiramand J, Barbier L, Delpero JR, Le Treut YP, et al. Duodenal gastrointestinal stromal tumors (GISTs): arguments for conservative surgery. J Gastrointest Surg. 2013;17(3):482–7.
El-Gendi A, El-Gendi S, El-Gendi M. Feasibility and oncological outcomes of limited duodenal resection in patients with primary nonmetastatic duodenal GIST. J Gastrointest Surg. 2012;16(12):2197–202.
Hoeppner J, Kulemann B, Marjanovic G, Bronsert P, Hopt UT, et al. Limited resection for duodenal gastrointestinal stromal tumors: surgical management and clinical outcome. World J Gastrointest Surg. 2013;5(2):16–21.
Shi H, Huang M, Wang Z, Zheng Y, Zhu Z, Sah B, et al. Clinicopathological and prognostic features of surgical management in duodenal gastrointestinal stromal tumors. Dig Surg. 2018;35:498–507.
Sugase T, Takahashi T, Nakajima K, Hirota S, Masuzawa T, Nishida T, et al. Clinicopathological characteristics, surgery and survival outcomes of patients with duodenal gastrointestinal stromal tumors. Digestion. 2016;94:30–6.
Lee SJ, Song KB, Lee YJ, Kim SC, Hwang DW, Lee JH, et al. Clinicopathologic characteristics and optimal surgical treatment of duodenal gastrointestinal stromal tumor. J Gastrointest Surg. 2018. https://doi.org/10.1007/s11605-018-3928-1.
Zhang S, Tian Y, Chen Y. Clinicopathological characteristics, surgical treatments, and survival outcomes of patients with duodenal gastrointestinal stromal tumor. Dig Surg. 2018. https://doi.org/10.1159/000488008.
Chen P, Song T, Wang X, Zhou H, Zhang T, Wu Q, et al. Surgery for duodenal gastrointestinal stromal tumors: a single-center experience. Dig Dis Sci. 2017;62(11):1–10.
Käthe Goossen TS, Probst P, et al. Optimal literature search for systematic reviews in surgery. Langenbeck's Arch Surg. 2018;403(1):119–29.
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
Gu L, Khadaroo PA, Chen M, Qian H, Zhu H, Li X, et al. Surgical management and outcomes of duodenal gastrointestinal stromal tumors. Acta Gastro-Enterol Belg. 2019;82(1):11–8.
Duffaud F, Meeus P, Bachet JB, Cassier P, Huynh TK, Boucher E, et al. Conservative surgery vs. duodeneopancreatectomy in primary duodenal gastrointestinal stromal tumors (GIST): a retrospective review of 114 patients from the French sarcoma group (FSG). Eur J Surg Oncol. 2014;40(10):1369–75.
Zhou B, Zhang M, Wu J, Yan S, Zhou J, Zheng S. Pancreaticoduodenectomy versus local resection in the treatment of gastrointestinal stromal tumors of the duodenum. World J Surg Oncol. 2013;11(1):1–6.
Tien YW, Lee CY, Huang CC, Hu RH, Lee PH. Surgery for gastrointestinal stromal tumors of the duodenum. Ann Surg Oncol. 2010;17(1):109–14.
Chok AY, Koh YX, Ow MYL, Allen JC Jr, Goh BK. A systematic review and meta-analysis comparing Pancreaticoduodenectomy versus limited resection for duodenal gastrointestinal stromal tumors. Ann Surg Oncol. 2014;21(11):3429–38.
Liang X, Shi LG, Hao J, Liu AA, Chen DL, Hu XG, et al. Risk factors and managements of hemorrhage associated with pancreatic fistula after pancreaticoduodenectomy. Hepatobiliary Pancreat Dis Int. 2017;16(5):537–44.
Su Z, Koga R, Saiura A, Natori T, Yamaguchi T, Yamamoto J. Factors influencing infectious complications after pancreatoduodenectomy. J Hepatobiliary Pancreat Sci. 2010;17(2):174–9.
Mañas-Gómez MJ, Rodríguez-Revuelto R, Balsells-Valls J, Olsina-Kissler JJ, Caralt-Barba M, Pérez-Lafuente M, et al. Post-pancreaticoduodenectomy hemorrhage. Incidence, diagnosis, and treatment. World J Surg. 2011;35(11):2543–8.
Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39(10):1411–9.
Brodsky SV, Gimenez C, Ghosh C, Melamed M, Ramaswamy G. Estrogen and progesterone receptors expression in gastrointestinal stromal tumors and intramural gastrointestinal leiomyomas. Int J Gastrointest Cancer. 2006;37(4):129–32.
Lam MM, Corless CL, Goldblum JR, Heinrich MC, Downs-Kelly E, Rubin BP. Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses. Int J Gynecol Pathol. 2006;25(3):288–92.
Lopes LF, Bacchi CE. Androgen receptor expression in gastrointestinal stromal tumor. Appl Immunohistochem Mol Morphol. 2009;17(2):146–50.
Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, et al. Correlation of kinase genotype and clinical outcome in the north American intergroup phase III trial of Imatinib Mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and leukemia group B and southwest oncology group. J Clin Oncol. 2008;26(33):5360–7.
Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42(8):1093–103.
Corless CL. PDGFRA mutations in gastrointestinal stromal tumors: frequency, Spectrum and in vitro sensitivity to Imatinib. J Clin Oncol. 2005;23(23):5357–64.